Scott & White Healthcare to participate in international trial investigating lung cancer treatment

September 16, 2010

Scott & White Healthcare in Round Rock, Texas is recruiting patients for a Phase III lung cancer trial aimed at preventing the disease's recurrence in previously treated patients. The trial will evaluate the potential of an immunotherapy called Antigen-Specific Cancer Immunotherapeutic (ASCI) for the treatment of Non-Small Cell Lung Cancer (NSCLC).

The MAGRIT (MAGE-A3 as Adjuvant Non-Small Cell LunG Cancer Immunotherapy) study is expected to be one of the largest Phase III trials ever conducted for NSCLC. Scott & White Healthcare - Round Rock is joining with 400 centers in more than 33 countries worldwide in this clinical research effort.

"The randomized, double-blind, placebo-controlled trial will enroll patients that demonstrate the MAGE-A3 biomarker and those who are assessed as stage IB, II, or IIIA resectable Non-Small Cell Lung Cancer," said Laura Beaty, M.D., principal investigator and hematology/oncologist at Scott & White Healthcare - Round Rock. "The ASCI administration will be started in patients after surgery and standard chemotherapy, and in patients who only receive surgery as a standard of care as the primary endpoint of the trial is disease-free survival," she said.

ASCI is an investigational class of cancer immunotherapy agents aimed at educating the patient's immune system to identify cancer cells in a specific manner. This investigational cancer immunotherapy is developed using tumor-specific antigens. "If a patient's cancer is found to express certain proteins/antigens, then the treatment educates their immune system to fight their cancer cells," explained Dr. Beaty.

"This study is a global undertaking and we are looking for patients to consider enrolling," said Dr. Beaty. "To reach our enrolment target of 2,270 patients, we'll need to screen more than 13,000 patients worldwide."
-end-
The trial has a target enrolment of 2,270 patients. For patients who are interested in this trial, please contact Jill Meredith, RN, OCN, CCRP or MeLissa Carney, CCRP, Scott & White Healthcare - Round Rock at 512-218-6374. Additional information can be found at www.immunotherapyforcancer.com.

About the Phase II NSCLC trial

The Phase II double-blind, placebo-controlled study is believed to be the first positive proof-of-concept for an ASCI in early Non-Small Cell Lung Cancer (NSCLC). The study randomized 182 patients with completely resected stages IB or II NSCLC to receive either MAGE-A3 ASCI or placebo in the adjuvant setting. All patients participating in the trial had cancers expressing a tumor-specific antigen known as MAGE-A3, which is present in approximately 35 percent to 50 percent of early NSCLC.1

In the Phase II clinical study, the most commonly reported adverse events were mild local (pain, redness, swelling) or systemic (fever, fatigue, muscle pain) reactions. Out of 182 patients, only three Grade 3 adverse events were rated as possibly related to the MAGE-A3 treatment. These events led to the withdrawal of only one patient for chronic obstructive pulmonary disease (COPD) exacerbation.

About MAGE-A3 ASCI

MAGE-A3 is a tumor-specific antigen that is expressed in a large variety of cancers with no expression in normal cells. The antigen has been found in about 30-50% of lung cancer patients. The high expression of MAGE-A3 in non-small cell lung cancer, as well as the high unmet medical need in this disease population prompted the development of the study ASCI antigen targeting the MAGE-A3.

MAGE-A3 ASCI is an investigational compound and it is not approved for use in any indication in any country at this time.

About Non-Small Cell Lung Cancer

According to the World Health Organization (WHO), more than 1.2 million new cases of lung and bronchus cancer are diagnosed each year worldwide. There were 386,300 new cases of lung cancer in Europe2 and 174,000 new cases of lung cancer in the U.S. in 2006 and 334,800 (Europe), 162,000 (U.S.) related deaths in the same year, causing lung cancer to remain the biggest killer in Europe.3

About Scott & White Healthcare

Scott & White Healthcare - Round Rock has over 15 ongoing clinical trials in a variety of medical specialties.

Scott & White Healthcare is a non-profit collaborative health care system established in 1897 and is the principal clinical teaching facility affiliated with the Texas A&M Health Science Center College of Medicine, with a Temple campus that includes a four-year medical curriculum. Along with its 636-bed flagship hospital and clinic facility in Temple, Texas, Scott & White includes 10 other hospitals or hospital partners, and over 60 clinic locations throughout Central Texas. With total staff exceeding 12,000, including over 1,200 physicians, scientists and health care providers, Scott & White has become one of the nation's largest multi-specialty group practice systems.

Scott & White Healthcare

Related Cancer Articles from Brightsurf:

New blood cancer treatment works by selectively interfering with cancer cell signalling
University of Alberta scientists have identified the mechanism of action behind a new type of precision cancer drug for blood cancers that is set for human trials, according to research published in Nature Communications.

UCI researchers uncover cancer cell vulnerabilities; may lead to better cancer therapies
A new University of California, Irvine-led study reveals a protein responsible for genetic changes resulting in a variety of cancers, may also be the key to more effective, targeted cancer therapy.

Breast cancer treatment costs highest among young women with metastic cancer
In a fight for their lives, young women, age 18-44, spend double the amount of older women to survive metastatic breast cancer, according to a large statewide study by the University of North Carolina at Chapel Hill.

Cancer mortality continues steady decline, driven by progress against lung cancer
The cancer death rate declined by 29% from 1991 to 2017, including a 2.2% drop from 2016 to 2017, the largest single-year drop in cancer mortality ever reported.

Stress in cervical cancer patients associated with higher risk of cancer-specific mortality
Psychological stress was associated with a higher risk of cancer-specific mortality in women diagnosed with cervical cancer.

Cancer-sniffing dogs 97% accurate in identifying lung cancer, according to study in JAOA
The next step will be to further fractionate the samples based on chemical and physical properties, presenting them back to the dogs until the specific biomarkers for each cancer are identified.

Moffitt Cancer Center researchers identify one way T cell function may fail in cancer
Moffitt Cancer Center researchers have discovered a mechanism by which one type of immune cell, CD8+ T cells, can become dysfunctional, impeding its ability to seek and kill cancer cells.

More cancer survivors, fewer cancer specialists point to challenge in meeting care needs
An aging population, a growing number of cancer survivors, and a projected shortage of cancer care providers will result in a challenge in delivering the care for cancer survivors in the United States if systemic changes are not made.

New cancer vaccine platform a potential tool for efficacious targeted cancer therapy
Researchers at the University of Helsinki have discovered a solution in the form of a cancer vaccine platform for improving the efficacy of oncolytic viruses used in cancer treatment.

American Cancer Society outlines blueprint for cancer control in the 21st century
The American Cancer Society is outlining its vision for cancer control in the decades ahead in a series of articles that forms the basis of a national cancer control plan.

Read More: Cancer News and Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.